Treatment of relapsed acute myeloid leukemia with MLL/AF6 fusion after allogeneic hematopoietic stem cell transplantation with gemtuzumab ozogamicin with a long interval followed by donor lymphocyte infusion

Leukemia. 2008 Jun;22(6):1273-4. doi: 10.1038/sj.leu.2405029. Epub 2007 Nov 8.

Authors

H Tamai, Y Shioi, H Yamaguchi, M Okabe, S Wakita, T Mizuki, K Nakayama, K Inokuchi, K Tajika, K Dan

PMID: 17989711
DOI: 10.1038/sj.leu.2405029

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Aminoglycosides / therapeutic use*
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Antineoplastic Agents / therapeutic use*
Chromosomes, Human, Pair 7 / genetics
Female
Gemtuzumab
Hematopoietic Stem Cell Transplantation*
Humans
Immunotoxins
Leukemia, Myeloid, Acute / genetics
Leukemia, Myeloid, Acute / therapy*
Lymphocyte Transfusion*
Myeloid-Lymphoid Leukemia Protein / genetics*
Neoplasm Recurrence, Local / drug therapy*
Oncogene Proteins, Fusion / genetics*
Time Factors
Tissue Donors
Translocation, Genetic
Transplantation, Homologous

Substances

Aminoglycosides
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Immunotoxins
MLL-AF6 fusion protein, human
Oncogene Proteins, Fusion
Myeloid-Lymphoid Leukemia Protein
Gemtuzumab